Loading
Latest filing published 15 Dec 2025 for Jaguar Health, Inc..
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by Anula Jayasuriya span 2 companies, the busiest being Jaguar Health, Inc. and Lineage Cell Therapeutics, Inc. Over a trading history stretching from 1 July 2023 to 11 December 2025, the count stands at 4 filings.
The open-market record is one-sided, with 1 purchase worth €9,848 and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 3 share grants.
The record was last updated on 15 December 2025 with a share grant in Jaguar Health, Inc. The last insider purchase was made public on 2 January 2024, 1,026 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations